The Depression, Anxiety, and Stress Scale (DASS) is a specialized psychometric tool designed to distinguish between three related but distinct negative emotional states. Unlike many tools that conflate these feelings, the DASS was developed by researchers at the University of New South Wales to provide a clearer, tripartite picture of a person’s mental well-being. 1. The Structure of the Scale
DASS-167, also known as 2-{[4-(4-aminopiperidin-1-yl)-3-bromophenyl]amino}-5-chlorobenzonitrile, is a small molecule inhibitor that has been designed to target the SARS-CoV-2 virus. The compound was first identified through a high-throughput screening campaign, which involved testing a large library of compounds against the viral enzyme, main protease (Mpro). Mpro is a crucial enzyme for the replication of the SARS-CoV-2 virus, and inhibiting its activity has been a key strategy for the development of COVID-19 therapeutics. DASS-167
Despite the new MRT line, many residents found that removing 167 meant longer walks to alternative bus stops or more transfers for specific routes. The Human Factor: The Depression, Anxiety, and Stress Scale (DASS) is
Measures physiological arousal, fear responses, and situational anxiety. The Structure of the Scale DASS-167, also known
In vivo studies have also demonstrated the efficacy of DASS-167 in mouse models of SARS-CoV-2 infection. Mice treated with DASS-167 showed a significant reduction in viral titers and lung inflammation compared to vehicle-treated controls. These findings suggest that DASS-167 has the potential to be developed as a therapeutic agent for the treatment of COVID-19.